NHL Clinical Trials

7 recruiting

NHL Trials at a Glance

33 actively recruiting trials for nhl are listed on ClinicalTrialsFinder across 6 cities in 11 countries. The largest study group is Phase 1 with 18 trials, with the heaviest enrollment activity in New York, Wuhan, and Tianjin. Lead sponsors running nhl studies include Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Ruijin Hospital, and National Cancer Institute (NCI).

Browse nhl trials by phase

Treatments under study

About NHL Clinical Trials

Looking for clinical trials for NHL? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new NHL trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about NHL clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 33 trials

Recruiting

Collection of Human Samples to Study Hairy Cell and Other Leukemias, and to Develop Recombinant Immunotoxins for Cancer Treatment

Chronic Lymphocytic Leukemia (CLL)Hairy Cell Leukemia (HCL)Non-Hodgkins Lymphoma (NHL)+2 more
National Cancer Institute (NCI)1,263 enrolled1 locationNCT01087333
Recruiting
Early Phase 1

A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

Chronic Lymphocytic Leukemia (CLL)B-cell Acute Lymphoblastic Leukemia (B-ALL)B-cell Non-Hodgkin's Lymphoma (B-NHL)
Grit Biotechnology28 enrolled2 locationsNCT07205315
Recruiting
Early Phase 1

A Clinical Study Exploring the Safety, Efficacy and Metabolic Kinetics of CT1182 Injection in Patients With Relapsed / Refractory Non Hodgkin Lymphoma

DLBCL - Diffuse Large B Cell LymphomaB-cell Non Hodgkin Lymphoma (NHL)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology24 enrolled1 locationNCT07548697
Recruiting
Phase 1

A Trial to Study if REGN5837 in Combination With Odronextamab is Safe for Adult Participants With Aggressive B-cell Non-Hodgkin Lymphomas

B-cell Non-Hodgkins Lymphoma (B-NHL)
Regeneron Pharmaceuticals91 enrolled20 locationsNCT05685173
Recruiting
Phase 2

Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders

AMLMDSHLH+6 more
Memorial Sloan Kettering Cancer Center31 enrolled1 locationNCT04644016
Recruiting
Phase 1Phase 2

CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies

Acute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaB-Non Hodgkin Lymphoma+2 more
National Cancer Institute (NCI)126 enrolled1 locationNCT05442515
Recruiting
Phase 1

A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.

Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Arvinas Inc.255 enrolled17 locationsNCT06393738
Recruiting
Phase 1

A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies

Lymphoma, B-CellChronic Lymphocytic Leukemia (CLL)Lymphoma, Non-Hodgkin (NHL)+1 more
Umoja Biopharma106 enrolled8 locationsNCT06528301
Recruiting
Phase 1

Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R/R B-NHL Patients

Non-Hodgkin LymphomaMantle Cell Lymphoma (MCL)CNS Lymphoma+1 more
University of Colorado, Denver68 enrolled1 locationNCT05098613
Recruiting
Early Phase 1

Clinical Study of LV009 Injection for the Treatment of Relapsed/Refractory CD19-Positive Hematologic and Lymphoid Malignancies

Acute Lymphoblastic Leukemia (ALL), AdultNon-Hodgkin Lymphoma (NHL)
PersonGen BioTherapeutics (Suzhou) Co., Ltd.19 enrolled1 locationNCT07312630
Recruiting
Phase 1

A Study to Assess PK, Safety and Efficacy of HSK47977 Tablets in Subjects With Relapsed or Refractory Non-Hodgkin's Lymphoma

NHL
Haisco Pharmaceutical Group Co., Ltd.110 enrolled1 locationNCT07283796
Recruiting
Not Applicable

SBU-RESET: RElaxation, Stress Reduction and Epigenetics Trial in Cancer Survivors

Colon CancerLung Cancer (Diagnosis)Lung Adenocarcinoma+8 more
Barbara Nemesure100 enrolled1 locationNCT07161713
Recruiting
Early Phase 1

An Open-label, Single-arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of OriV508 Injection in Treating Relapsed/Refractory Hematological Malignancies

Non-Hodgkin Lymphoma (NHL)Multiple Myeloma (MM)
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology40 enrolled1 locationNCT07101705
Recruiting
Phase 1Phase 2

Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma

B-cell Non-Hodgkin Lymphoma (B-NHL)
Cellectis S.A.80 enrolled10 locationsNCT05607420
Recruiting
Phase 1Phase 2

T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin LymphomaNon-Hodgkin's LymphomaLymphomas Non-Hodgkin's B-Cell+2 more
Estrella Biopharma, Inc.21 enrolled2 locationsNCT06343311
Recruiting
Not Applicable

Integrated Radiotherapy-optimized ASCT Sequential CAR-T Therapy for Patients With Relapsed and Refractory B-NHL

Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)
The First Affiliated Hospital of Soochow University20 enrolled1 locationNCT07059741
Recruiting
Phase 2

A Randomized Phase II Study of Hyperbaric Oxygen in Improving Engraftment in Umbilical Cord Blood Stem Cell Transplant

AMLHodgkin DiseaseNHL
University of Rochester64 enrolled1 locationNCT03739502
Recruiting
Not Applicable

JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia

B-ALLB-NHL
Tongji Hospital20 enrolled1 locationNCT06689917
Recruiting
Phase 1Phase 2

IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers

Multiple MyelomaNHLRefractory Non-Hodgkin Lymphoma+1 more
Indapta Therapeutics, INC.128 enrolled12 locationsNCT06119685
Recruiting
Phase 1Phase 2

The Application of CAR-T Cell Therapy in Relapsed and Refractory Malignant Hematologic Tumors

AML (Acute Myelogenous Leukemia)Lymphoma, B-cell, Aggressive Non-Hodgkin (B-NHL)
Tianjin Medical University General Hospital90 enrolled1 locationNCT06911710